此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

补充雌马酚对健康志愿者动脉硬度和认知的影响 (ACE)

2026年11月3日 更新者:Akira Sekikawa

动脉硬度、认知和雌马酚

The ACE Trial, funded by the National Institute on Ageing/National Institutes of Health (NIH), is a multicenter clinical trial. The ACE Trial will determine if taking the dietary supplement Equol could slow the progression of stiffening of the arteries, small blood vessel disease in the brain and memory decline. Equol is a soy-based supplement that has plant estrogen-like compounds in it.

Equol is a metabolite of soy isoflavone. Our studies in Japan and other studies suggest that Equol may slow mechanisms related to memory decline. No previous studies in the United States have tested the effect of Equol on these mechanisms or memory decline. Supplementation of Equol in the ACE Trial is approved by the Food and Drug Administration (FDA).

Researchers at the University of Pittsburgh, Pittsburgh, Pennsylvania, Wake Forest University, Winston-Salem, North Carolina, and Emory University, Atlanta, Georgia, are recruiting participants.

The ACE Trial will ask participants to complete 7 clinic visits over a two-year period. The participants are asked to take Equol tablets daily for 24 months. Clinic procedures include Pulse Wave Velocity (to measure arterial stiffness), Magnetic Resonance Imaging (MRI) of the brain and tests of awareness and thinking.

研究概览

详细说明

The ACE trial is an early-stage multi-center randomized controlled trial (RCT) designed to test the effect of a 24-month intervention of 10 mg/day equol supplementation on arterial stiffness, white matter lesions (WMLs) in the brain and cognitive decline among 400 individuals aged 65 and 85 without dementia. Recent studies in Japan reported that a diet high in soy and soy isoflavones is inversely associated with incident cognitive impairment and dementia. The Women's Isoflavone Soy Health (WISH) in the US, an RCT of soy isoflavones, however, showed no significant effect on cognition. We posit that the discrepant result is due to the difference in equol-producing capability. Equol, a metabolite of soy isoflavone daidzein transformed by the gut microbiome, is the most bioactive among all soy isoflavones and their metabolites. 50-70% of Japanese convert daidzein to equol in contrast to 20-30% of Americans. Arterial stiffness, a significant predictor of cognitive decline, is significantly improved in a short-duration RCT of 10 mg/day equol supplementation in middle-aged subjects. WMLs are a risk factor for age-related cognitive decline and dementia. We reported a longitudinal association of equol-producing status with WML% (WML volume normalized to total brain volume) in cognitively normal elderly in Japan. The subgroup analysis of WISH showed that equol producers had better cognition than the control group, suggesting that equol may slow cognitive decline. No previous study has tested the effect of equol supplementation on arterial stiffness, WMLs or cognitive decline in older adults.

研究类型

介入性

注册 (实际的)

369

阶段

  • 阶段2

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • Georgia
      • Atlanta、Georgia、美国、30322
        • Emory University
    • North Carolina
      • Winston-Salem、North Carolina、美国、27157
        • Wake Forest University Health Sciences
    • Pennsylvania
      • Pittsburgh、Pennsylvania、美国、15213
        • University of Pittsburgh

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

65年 至 85年 (年长者)

接受健康志愿者

是的

有资格学习的性别

全部

描述

Inclusion Criteria:

Men and women age between 65 and 85 at entry of European Americans or African Americans

Inclusion criteria via screening visit:

  • Individuals who are able to provide informed consent
  • Individuals who are willing to be randomized to the intervention or placebo group

Exclusion Criteria:

Exclusion criteria via initial screening by phone

  • Individuals who are regularly taking isoflavone supplements or eat soy product ≥ 2 times a week (by specific questionnaire)
  • Individuals who do not agree to maintain isoflavone supplements or soy product intake described above during the study period.
  • Individuals who have allergy or intolerance to soy isoflavones.
  • Individuals whose score for the Telephone Interview for Cognitive Status is 22 and below.
  • Individuals with stroke, neurological disorders, bipolar disease whether or not under medical treatment, cancer treatment in the past 6 months, head trauma or other condition which is not appropriate for the study (e.g., contraindication to magnetic resonance imaging (MRI)).
  • Individuals with untreated depression
  • Individuals with atrial fibrillation
  • Individuals with heart failure
  • Individuals with heart attack or coronary intervention in the past 6 months
  • Individuals with carotid endarterectomy or peripheral artery disease
  • Individuals currently undergoing treatment for pulmonary embolism or deep vein thrombosis
  • Individuals with aortic (abdominal, thoracic) aneurysm
  • Individuals with inflammatory bowel diseases
  • Individuals currently undergoing hemodialysis
  • Women with a past or family history of breast cancer.*1
  • Women on estrogen replacement therapy
  • Individuals unable to lay supine for 30-60 minutes
  • Individuals with weight ≥300 lbs
  • Individuals who are planning to move out of the area in the next 2 years
  • Individuals who participated in another clinical trial in the past 3 months

Exclusion criteria via screening visit

  • Individuals with Quick Dementia Rating System (QDRS) score ≥ 6.0
  • Individuals who are regularly taking isoflavone supplements or eat soy product ≥ 2 times a week (by specific questionnaire)
  • Individuals who do not agree to maintain isoflavone supplements or soy product intake described above during the study period.
  • Individuals who have allergy or intolerance to soy isoflavones.
  • Blood pressure (BP) - systolic BP ≥ 180 mmHg or diastolic BP ≥ 110 mmHg
  • Heart rate ≥110 or ≤40
  • Hemoglobin <10 g/dL
  • HbA1c ≥ 7.5%
  • Blood creatinine > 2.0 mg/dL
  • Liver function tests > 2 X upper limit of normal
  • Abnormal thyroid function (Thyroid Stimulating Hormone)
  • Vitamin B12 levels ≤ 210 pg/mL
  • Hematocrit <30%
  • White blood cell count <3,000 or >15,000
  • Platelet count <100,000 or >600,000
  • Urinary protein ≥ + by dipstick
  • Any condition or therapy which, in the opinion of the investigator, might pose a risk to the participant or make participation in the study not in the participant's best interest

In addition, individuals with the following condition will be excluded because these conditions do not allow subjects to undergo examinations the investigators proposed in the project:

  • Those who are contraindicated for 3 Tesla (3T) structural brain magnetic resonance imaging (MRI) such as pacemakers.
  • Atrial fibrillation because pulse wave velocity is not accurately measured.
  • Hearing impairment which interferes with cognitive testing
  • Vision impairment which interferes with cognitive testing

Exclusion criteria at structural brain MRI Any other conditions which, in the opinion of the investigator, might pose a risk to the participant or make participation in the study not in the participant's best interest

*1 Few studies have investigated the association of equol, a metabolite of soy isoflavone daidzein, with breast cancer. These studies reported no significant association of serum or urine equol with the risk of breast cancer. Dietary intake of soy and soy isoflavones is generally considered to have benefits for menopausal symptoms, cardiovascular health, bone health, and cancers of the breast and prostate. Observational studies show that soy consumption is associated with a reduced risk of many cancers including breast cancer. Moreover, a prospective cohort study of 6,000+ North American women with breast cancer showed that dietary intake of soy and isoflavones was associated with reduced all-cause mortality. However, there is little evidence to support that the use of supplements containing soy isoflavones or soy protein powder to reduce cancer risk. A recent large prospective cohort study in France reported that supplementation of soy isoflavones increased the risk of estrogen receptor-negative breast cancer, especially among women who had a history of breast cancer in first-degree relatives.

Exclusion criteria at the baseline visit

The investigators recruit subjects without dementia. Thus, at the initial screening by phone, the investigators exclude individuals whose score for the Telephone Interview for Cognitive Status is 22 and below. Then, at the screening visit, investigators will exclude individuals with a Quick Dementia Rating System score ≥ 6.0.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:预防
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:四人间

武器和干预

参与者组/臂
干预/治疗
实验性的:Equol Arm

S-equol - 10 mg per day tablet for 24 months.

Experimental drug

其他名称:
  • 埃奎勒
安慰剂比较:Placebo Arm

10 mg per day for 24 months of tablets that will be of the same size/shape/color as the experimental tablet.

Placebo - 10 mg per day for 24 months of tablets that will be the same size/shape/color as the s-equol tablets.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Change in arterial stiffness
大体时间:Change from baseline in arterial stiffness at 12 months

Arterial stiffness describes the rigidity of the arterial wall and is a significant predictor of cognitive decline. Arterial stiffness will be measured by pulse wave velocity (m/s) with a SphygmoCor device (Sydney, Australia). The range of pulse wave velocity is from 5 to 20 m/s.

Change from baseline in arterial stiffness at 12 months
Change in arterial stiffness
大体时间:Change from baseline in arterial stiffness at 24 months

Arterial stiffness describes the rigidity of the arterial wall and is a significant predictor of cognitive decline. Arterial stiffness will be measured by pulse wave velocity (m/s) with a SphygmoCor device (Sydney, Australia). The range of pulse wave velocity is from 5 to 20 m/s.

Change from baseline in arterial stiffness at 24 months

次要结果测量

结果测量
措施说明
大体时间
Change in white matter lesion (WML) volume percent
大体时间:Change from baseline in WML volume percent at 24 months

WMLs are a significant predictor of cognitive decline. WMLs will be measured using an automated brain magnetic resonance imaging method. WML volume percent will be calculated by dividing WML volume by total brain volume as a percentage. The range of WML volume percent is from 0 to 4.2%.

Change from baseline in WML volume percent at 24 months
Change in cognitive score measured by the Preclinical Alzheimer's Cognitive Composite-5 (PACC-5) score
大体时间:Change from baseline in cognitive score measured by the PACC-5 at 12 months

The PACC-5 is a composite neuropsychological measure optimized to detect subtle changes over time in cognitively unimpaired older adults. The range of PACC-5 score is from -3 to 3.

Change from baseline in cognitive score measured by the PACC-5 at 12 months
Change in cognitive score measured by the Preclinical Alzheimer's Cognitive Composite-5 (PACC-5) score.
大体时间:Change from baseline in cognitive score measured by the PACC-5 at 24 months

The PACC-5 is a composite neuropsychological measure optimized to detect subtle changes over time in cognitively unimpaired older adults. The range of PACC-5 score is from -3 to 3 where 3 represents better cognition.

Change from baseline in cognitive score measured by the PACC-5 at 24 months

其他结果措施

结果测量
措施说明
大体时间
Change in NIH Toolbox (NIH-TB) cognition battery score
大体时间:Change from baseline in NIH-TB cognition battery score at 12 months

NIH-TB Cognition battery, comprised of computerized tests of fluid and crystallized cognitive abilities, via proctored iPad administration.

Change from baseline in NIH-TB cognition battery score at 12 months
Change in NIH Toolbox (NIH-TB) cognition battery score
大体时间:Change from baseline in NIH-TB cognition battery score at 24 months

NIH-TB Cognition battery, comprised of computerized tests of fluid and crystallized cognitive abilities, via proctored iPad administration.

Change from baseline in NIH-TB cognition battery score at 24 months
Changes in select brain markers other than white matter lesion (WML) volume percent
大体时间:Change from baseline in brain markers other than WML volume percent at 24 months

Brain markers other than WML volume percent will be measured using MRI, including cerebral blood flow, venous oxygenation, white matter organization lacunar infarct and cortical thickness.

Change from baseline in brain markers other than WML volume percent at 24 months
Change in ultrasound measurements of carotid artery
大体时间:Change from baseline in ultrasound measurements of carotid artery at 24 months

Ultrasound measurements of carotid artery include carotid plaque and intima-media thickness. Investigators will use a high-resolution ultrasound system equipped with a variable frequency transducer (NextGen LOGIQ*e R7).

Change from baseline in ultrasound measurements of carotid artery at 24 months
Change in select plasma biomarkers
大体时间:Change from baseline in select plasma biomarkers at 24 months

Plasma biomarkers of inflammation and endothelial function (C-reactive protein, intracellular adhesion molecule, vascular cell adhesion molecule, glial fibrillary acidic protein, neurofilament light) as well as amyloid-β40, amyloid-β42 and phosphorylated tau 181 will be measured.

Change from baseline in select plasma biomarkers at 24 months

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Akira Sekikawa, MD, PhD, PhD、University of Pittsburgh

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2023年6月29日

初级完成 (实际的)

2026年10月29日

研究完成 (估计的)

2027年1月31日

研究注册日期

首次提交

2023年2月13日

首先提交符合 QC 标准的

2023年2月13日

首次发布 (实际的)

2023年2月23日

研究记录更新

最后更新发布 (实际的)

2026年11月5日

上次提交的符合 QC 标准的更新

2026年11月3日

最后验证

2026年8月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

是的

IPD 计划说明

The Center for Clinical Trial & Data Coordination (CCDC), University of Pittsburgh, has rich experience as the Data Core (DC) for other NIH-funded studies, in reporting to and providing final datasets for an NIH Central Data Repository. The final dataset(s) will include demographic and clinical data at baseline, study arm assignment, and all primary and secondary outcomes for the ACE trial. The final dataset(s) will be completely de-identified. These data will be released to an NIH Central Data Repository no later than 1 year after the end of the clinical activity (final patient follow-up, etc.) or immediately after the main paper of the trial has been published, whichever comes first. The files available will include original copies of the case report forms, a detailed codebook of variable names, value labels, formats, missing data reports, and linkage files for samples. The analytic dataset may also include derived variables that were created during the analytic process.

IPD 共享时间框架

The final dataset(s) will be completely de-identified. These data will be released to an NIH Central Data Repository no later than 1 year after the end of the clinical activity (final patient follow-up, etc.) or immediately after the main paper of the trial has been published, whichever comes first.

IPD 共享访问标准

Data Requestors must agree to the terms of the ACE Data Use Agreement (DUA) and will be asked to complete an online application for access to anonymized datasets. The agreement will be reviewed by the ACE Trial Steering Committee (SC).

The ACE SC approval of the Data Requestor's Data Sharing Agreement request will trigger a process that allows access to the files described above and provides the requestor with an email notification of the review decision. All data and supporting documents selected by the project leadership for sharing will be made available for approved applicants to download. The review committee may require requestors to provide an annual update on their use of project data, to submit manuscripts for SC review and/or may revoke access for investigators who do not respond to annual update requests.

IPD 共享支持信息类型

  • 研究方案
  • 树液
  • 国际碳纤维联合会

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅